^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Oncophage (Heat Shock Protein Peptide Complex-96)

    i
    Other names: Heat Shock Protein Peptide Complex-96, G-100, HSPPC-96, NP-150, Prophage series, G-200, gp96 heat shock protein-peptide complex vaccine
    Associations

    News

    Trials
    Company:
    Agenus
    Drug class:
    Tumor-associated antigen inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=90, Terminated, Alliance for Clinical Trials in Oncology | Active, not recruiting --> Terminated; DSMB futility analysis
    Trial termination
    |
    Avastin (bevacizumab) • Oncophage (Heat Shock Protein Peptide Complex-96)
    over1year
    Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P2, N=90, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Dec 2022
    Trial completion • Trial completion date • Surgery
    |
    PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
    over2years
    Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=310 --> 74
    Clinical • Enrollment closed • Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
    3years
    Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P2, N=310, Recruiting, National Cancer Institute (NCI) | N=108 --> 310 | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Mar 2022 --> Jan 2023
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
    over3years
    Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P2, N=108, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
    4years
    Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P2, N=108, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting | N=14 --> 108
    Clinical • Enrollment open • Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)